Pharmacokinetic Effects of Oral DMAA

University of Memphis

Status: Completed

Conditions: Outcomes of Single Oral Dose

Treatments: Dietary Supplement: DMAA

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01765933

DMAA Pharmacokinetics

Details and patient eligibility

About

1,3-dimethylamylamine (DMAA) has become increasingly popular as a component of dietary supplements. It is also used within "party pills," often in conjunction with alcohol and other drugs, and has been associated with untoward effects when abused at high dosages. To our knowledge, no studies have been conducted to determine the combined pharmacokinetic profile and physiologic responses of DMAA. To conclude on the safety profile of DMAA based solely on case reports would be problematic, in particular when accepting testimony from patients in uncontrolled environment, potentially under the influence of alcohol and other drugs. This is especially true in light of the fact that no prospective studies have shown these effects. Hence, the intent of the present study was to determine the pharmacokinetic profile of a single 25mg oral dosage of DMAA alone through 24 hours post-ingestion. This represents a typical dosage within one serving of many popular dietary supplements containing DMAA.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• must be able to swallow pill

Exclusion criteria

• self-reported cardiovascular or metabolic problems
• current smokers

Trial design

8 participants in 1 patient group

DMAA

Experimental group

Description:

Single oral dose 25 mg DMAA

Treatment:

Dietary Supplement: DMAA